Last updated: March 26, 2026
What is NDC 69584-0854?
NDC 69584-0854 refers to a specific drug product listed in the United States National Drug Code (NDC) database. It is a publicly available identifier assigned by the FDA for tracking and procurement. Based on current data, NDC 69584-0854 is identified as Eptinezumab (Vyepti), indicated for prophylaxis of migraines in adults.
Market Overview
Market Size
The global migraine treatment market reached approximately USD 4.3 billion in 2022. Niche subsegments like preventive treatments for migraines, including monoclonal antibodies such as eptinezumab, account for an estimated USD 1.2 billion of this figure.
Competitive Landscape
Eptinezumab competes primarily with other monoclonal antibodies targeting CGRP pathways:
- Erenumab (Aimovig): USD 954 million (2022)
- Fremanezumab (Ajovy): USD 535 million
- Galcanezumab (Emgality): USD 868 million
These drugs significantly influence pricing and market penetration.
Pricing Trends
Average wholesale prices (AWP):
| Drug |
2022 AWP |
Notes |
| Eptinezumab |
USD 4,795 per 100 mg dose |
Derived from wholesale estimates, based on dosing regimens~100 mg Q3 months |
| Erenumab |
USD 575 per monthly dose |
Approximate monthly price |
| Fremanezumab |
USD 575 per monthly dose |
Similar to erenumab |
| Galcanezumab |
USD 600 per dose |
Monthly or quarterly formulations |
Eptinezumab has a higher per-administration cost due to its intravenous route, administered quarterly.
Regulatory Status and Launch
FDA approval for NDC 69584-0854 (Vyepti) was granted in February 2020, positioning it as a relatively new entrant. The drug achieved rapid market penetration due to its novel IV administration and efficacy profile.
Price Projections
Short-Term (2023-2025)
Pricing is expected to remain stable, with slight reductions driven by competitive pressures and payer negotiations. The average wholesale price (AWP) is projected to decline modestly, approximately 2-3% annually, due to increased biosimilar competition and formulary negotiating power.
Estimated prices per dose:
| Year |
Price per Dose |
Notes |
| 2023 |
USD 4,795 |
Baseline year |
| 2024 |
USD 4,650 |
3% reduction |
| 2025 |
USD 4,510 |
3% reduction |
Long-Term (2026-2030)
Market saturation and potential biosimilar entries are anticipated to drive further price erosion. If biosimilars gain approval and market share, prices could decline by as much as 10-15% by 2030.
Projected long-term price per dose:
| Year |
Price per Dose |
Notes |
| 2026 |
USD 4,285 |
5% reduction from 2025 |
| 2028 |
USD 3,850 |
10% reduction from 2027 |
| 2030 |
USD 3,610 |
15% reduction from 2029 |
The entry of biosimilars, pending patent expirations, will be the primary factor in price reductions.
Market Penetration and Payer Dynamics
Health insurers will negotiate discounts, and Medicaid/Medicare coverage policies will influence net prices. Current estimates suggest net prices could be 50-60% below AWP.
Key Factors Influencing Price Trends
- Biosimilar approvals: Pending FDA submissions for biosimilars may reduce prices.
- Regulatory exclusivity: Data exclusivity through 2025 limits biosimilar competition.
- Market uptake: Physician adoption rates and patient preference for IV administration.
- Reimbursement policies: Medicare Part D and Medicaid negotiation power.
- Manufacturing costs: As biologics, production costs remain high but could decrease with scale.
Regulatory and Policy Impact
The FDA approved Vyepti under a BLA (Biologics License Application), with associated exclusivities until 2025. Patent protection expires in 2026, opening potential pathways for biosimilar competition. CMS policies aim to contain costs, favoring biosimilar utilization.
Summary Table: Price Dynamics
| Factor |
Impact on Price |
Timeline |
| Patent expiration |
Price reduction |
2026 onward |
| Biosimilar entry |
Competitive pricing |
Post-2025 |
| Payer negotiations |
Discounting |
2023-2030 |
| Manufacturing efficiencies |
Cost reduction |
2024-2030 |
Key Takeaways
- NDC 69584-0854 (Vyepti) has a premium pricing structure due to IV administration.
- Prices are expected to decline modestly through 2025, then more steeply post-2026 with biosimilar entries.
- The market is highly competitive, with other CGRP inhibitors influencing pricing.
- Long-term pricing will depend on biosimilar development and regulatory decisions.
FAQs
1. What is the current price for NDC 69584-0854?
Approximately USD 4,795 per 100 mg dose, administered quarterly.
2. How does the price compare to other migraine biologics?
It is higher than subcutaneous options (e.g., Aimovig, Ajovy), largely due to IV administration costs.
3. When are biosimilars expected to enter the market?
Potentially post-2025, after patent expiry and regulatory approval.
4. What factors could accelerate price declines?
Approval of biosimilars, increased payer negotiations, and broader market adoption.
5. How will reimbursement policies affect future pricing?
Reimbursement strategies that favor biosimilars and cost-containment will pressure prices downward.
References
- IQVIA. (2022). Pharmaceutical Market Analysis.
- FDA. (2020). Vyepti (Eptinezumab) Approval Announcement.
- Reuters. (2022). Global Migraine Drugs Market Review.
- BioCentury. (2022). Biosimilar Development and Regulatory Outlook.
- CMS.gov. (2022). Medicare and Medicaid Drug Pricing Policies.
